Mediclinic International PLC (LON:MDC) was downgraded by analysts at J P Morgan Chase & Co to a “neutral” rating in a report issued on Thursday, Marketbeat reports. They currently have a GBX 733 ($9.74) price target on the stock, down from their prior price target of GBX 898 ($11.93). J P Morgan Chase & Co’s price objective suggests a potential upside of 14.44% from the company’s current price.

A number of other brokerages have also recently commented on MDC. Citigroup Inc. reaffirmed a “neutral” rating and set a GBX 790 ($10.50) target price on shares of Mediclinic International PLC in a report on Tuesday, June 27th. Investec cut shares of Mediclinic International PLC to a “hold” rating and set a GBX 775 ($10.30) target price for the company. in a report on Monday, June 26th. Morgan Stanley cut shares of Mediclinic International PLC to an “equal weight” rating and reduced their target price for the company from GBX 825 ($10.96) to GBX 775 ($10.30) in a report on Thursday, June 29th. Credit Suisse Group reaffirmed a “neutral” rating on shares of Mediclinic International PLC in a report on Friday, July 21st. Finally, Jefferies Group LLC reduced their target price on shares of Mediclinic International PLC from GBX 650 ($8.64) to GBX 550 ($7.31) and set an “underperform” rating for the company in a report on Monday, September 25th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the stock. The company has an average rating of “Hold” and a consensus price target of GBX 740.89 ($9.84).

Mediclinic International PLC (LON:MDC) traded down 0.54% on Thursday, hitting GBX 640.50. 1,529,405 shares of the stock were exchanged. The stock’s market cap is GBX 4.72 billion. The company has a 50-day moving average of GBX 690.08 and a 200-day moving average of GBX 746.75. Mediclinic International PLC has a 12 month low of GBX 630.00 and a 12 month high of GBX 941.50.

WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/22/mediclinic-international-plc-mdc-cut-to-neutral-at-j-p-morgan-chase-co.html.

Mediclinic International PLC Company Profile

Mediclinic International plc is an international private healthcare provider. The Company’s segments include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate. It focuses on providing acute care and multidisciplinary healthcare services. It has interest in Spire Healthcare, a United Kingdom-based private healthcare company.

Analyst Recommendations for Mediclinic International PLC (LON:MDC)

Receive News & Ratings for Mediclinic International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International PLC and related companies with MarketBeat.com's FREE daily email newsletter.